Asset profile
cagrilintide
Peptide
Evidence outlook · registrational
Obesity: registrational readout pending
Entered Phase 3 on reliable signal mid-stage evidence. Registrational readout expected around 2027-05-11.
NCT03856047: The trial randomized participants to five active doses, a pooled placebo, and an active liraglutide comparator arm, with quadruple-blinding (participant, care provider, investigator, and outcomes assessor all masked) and roughly 100 participants per arm. The primary endpoint, percent change in body weight at 26 weeks, is the regulator-accepted physiological measure for obesity trials, and every cagrilintide dose showed a statistically significant weight-loss advantage over placebo (p-values ranging from 0.0002 to <.0001), so the primary comparison was clearly met in the favorable direction.
Also in development:Chronic Kidney Disease · Phase 2Type 2 Diabetes · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
180 competitors in this universe: 12 direct rivals (same mechanism and indication), 0 same-class, 168 same-indication; 59 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Cagrilintide: this drug | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| AZD6234 | Phase 3 | Peptide | Amylin receptor | ||
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| Eloralintide | Phase 3 | Peptide | Amylin receptor | ||
| MET-097i | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| Petrelintide | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | ||
| ABBV-295 | Phase 2 | Peptide | Amylin receptor | ||
| GUB-UCN2 | Phase 1/2 | Peptide | Amylin receptor | ||
| MET-233i | Phase 1/2 | Peptide | Amylin receptor | ||
| RM-718 | Phase 1/2 | Peptide | Amylin receptor | ||
| BGM1812 | Phase 1 | Peptide | Amylin/calcitonin receptor (dual) | ||
| GUB014295 | Phase 1 | Peptide | Amylin receptor | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor |
…and 165 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
6 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (7)
January 2027 (1)
April 2027 (1)
May 2027 (4)
What to watch
What to watch
November 2027 (1)
2028 (2)
2030 (1)
March 2030 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.